Neurable, the Boston-based neurotechnology firm, has secured a $35 million Series A funding round, pushing its total capital raised to $65 million. The investment, led by Spectrum Moonshot Fund, is a major validation for the burgeoning consumer brain-computer interface (BCI) market, signaling that investors are ready to back companies moving neural tracking out of specialized labs and into everyday wearables.
The core of Neurable’s strategy is its patented ‘Neurable AI,’ a compact brain-signal processing technology designed to integrate seamlessly into existing consumer electronics, most notably headphones. The company’s mission is straightforward: to make cognitive health insights, such as mental fatigue, focus levels, and recovery state, as accessible and common as checking a smartwatch for heart rate or sleep quality.
This latest Neurable funding arrives shortly after the launch of the MW75 Neuro LT, a pair of premium headphones equipped with BCI capabilities, alongside a redesigned app that provides real-time cognitive insights. According to the company, these capabilities have been rigorously validated through independent evaluations and peer-reviewed studies, demonstrating high fidelity in detecting subtle changes in cognitive state.
“Our mission is to make understanding your brain as natural and intuitive as checking your steps,” said Dr. Ramses Alcaide, CEO and Co-Founder of Neurable. He noted that the funding will allow the company to scale Neurable AI into new devices and industries, transforming cognitive health into a daily utility.
Investor confidence stems from Neurable’s ability to translate complex scientific breakthroughs into an elegant, functional consumer product. Mauro Guebeli, Investment Manager at Spectrum Value Management, highlighted the team’s achievement in bringing high-quality BCI technology into a desirable consumer form factor, powered by robust signal-processing algorithms.